Caribou Biosciences，Inc (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today presented updated clinical data from the ongoing ANTLER Phase 1 trial that indicates a single dose of CB-010, a readily available, off-the-shelf anti-CD19 CAR-T cell therapy with a PD-1 knockout, has the potential to rival the safety, efficacy, and durability of approved autologous CAR-T cell therapies.

Caribou Biosciences，Inc（纳斯达克：CRBU），一家领先的临床阶段CRISPR基因组编辑生物制药公司，今天提供了正在进行的鹿茸1期试验的最新临床数据，该试验表明单剂量CB-010是一种现成的，现成的抗CD19 CAR-T细胞疗法，PD-1敲除，有可能与经批准的自体CAR-T细胞疗法的安全性，有效性和耐久性相媲美。

The clinical results are being presented during a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. “The Phase 1 data from the ANTLER trial continues to be encouraging in terms of both safety and efficacy of an allogeneic CAR-T cell therapy,” said Boyu Hu, MD, director of lymphoma and CLL in the division of hematology and hematologic malignancies at the University of Utah and an investigator on the ANTLER trial.

临床结果将在2024年美国临床肿瘤学会（ASCO）年会的海报展示中展示。“从同种异体CAR-T细胞疗法的安全性和有效性来看，ANTLER试验的第一阶段数据仍然令人鼓舞，”犹他大学血液学和血液恶性肿瘤科淋巴瘤和CLL主任兼ANTLER试验研究人员Boyu Hu医学博士说。

“The partial human leukocyte antigen, or HLA, matching strategy is incredibly intriguing and further evaluation.

“部分人类白细胞抗原或HLA匹配策略非常有趣，需要进一步评估。